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detected in 36, 47, and 17% of pts and 34, 47, and 19% of donors,
respectively. G2677T polymorphism included GG, GT and TT
genotypes that were detected in 29, 55, and 16% of pts and 34, 49,
and 17% of donors, respectively. The cumulative incidence of
acute GVHD grade III-IV was 38% (24-62), 18% (9-35) and 18%
(6-50), when the donors had CC, CT and TT in the C3435T site,
respectively (p0.02). Multivariable analysis determined donor
CC (HR 2.4, p0.05) and alloSCT from female to male (HR 5.1,
p0.03) as the most signiﬁcant factors predicting for severe acute
GVHD while donor, disease and conditioning type were not sig-
niﬁcant. The overall incidence of grade II-IV GVHD was not
statistically different between the genotypes. Pt C3435T polymor-
phism and pt or donor G2677T polymorphisms had no correlation
with GVHD. The cumulative incidence of chronic GVHD was
84% (95%CI, 68-100), 53% (38-75) and 38% (39-63) when the
donors had CC, CT and TT in the C3435T site, respectively
(p0.02). Multivariable analysis determined donor CC (HR 2.2,
p0.01), alloSCT from female to male (HR 2.5, p0.03) and
unrelated donor (HR 1.8, p0.05) as the most signiﬁcant factors
predicting for chronic GVHD. The CC genotype in C3435T is
known to be associated with higher expression level of P-glycop-
rotein (Pgp). We speculate that increased Pgp may result in lower
intracellular levels of cyclosporine in donor T-cells leading to
higher incidence of GVHD. Furthermore, Pgp may be involved in
transporting cytokines that are critical to the pathogenesis GVHD.
Further studies will be required to determine the mechanism of the
association of C3435T polymorphism, Pgp expression and
GVHD. In conclusion, C3435T polymorphism in the MDR1 gene
may be an important factor in predicting GVHD and may be
considered when selecting the most suitable donor.
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The reactivity of NK cells and some T cell populations is regu-
lated by KIR interactions with HLA class I molecules. Such inter-
actions have been suggested to inﬂuence outcomes after alloBMT.
However, the effect of KIR interactions on the development of
cGVHD after MUD alloBMT has not been well described. We
analyzed 30 pts who received a 12/12 HLA MUD T-cell depleted
myeloablative alloBMT at our institution from 5/5/95-2/6/04.
Diagnoses included 17 AML, 6 ALL, 4 CML and 3 MDS. GVHD
prophylaxis consisted of Tacrolimus and methotrexate (5 mg/m2
days 1, 3, 6 and 11). The median age was 40 (range, 19-58). KIR
genotypes were determined for donors by PCR-RSSOP analysis.
Recipient HLA KIR ligands were categorized as: 1) HLA-Cw
groups C1 ( or -); 2) C2 ( or -); 3) HLA-Bw4 ( or -); and 4)
HLA-A3 or -A11 ( or -) [as reviewed by Farag et al. Blood 2002;
100:1935-47]. Donor KIR genotype and recipient HLA KIR li-
gands were used to generate an inhibitory KIR score for pts from
1 to 4 corresponding to the potential number of donor inhibitory
KIRs engaged with recipient HLA KIR ligands. Eight pts had a
score of 1, 11 had a score of 2, 9 had a score of 3 and 2 had a score
of 4. The Kaplan-Meier method was used to estimate the achieve-
ment of cGVHD by inhibitory KIR score. Pts with a score of 1-2
compared to those with a score of 3-4 were more likely at 6 mos to
develop cGvHD (71% vs. 0%, respectively, p0.002)and extensive
cGvHD (48% vs. 0%, respectively, p0.06). Only 1 (9%) pt with
a score of 3-4 developed cGvHD (limited stage) at 29.9 mos while
7 (37%) with a score of 1-2 developed cGvHD (4 extensive stage)
at a median of 3.8 mos (range, 3.3-7.6). No differences were found
between these 2 groups regarding the development of grade 2-4 or
grade 3-4 acute GVHD or with regards to age, race, sex, number
of prior chemotherapies, disease status at BMT, preparative regi-
men, total nucleated and CD34 cell doses. Pts with lower inhib-
itory KIR scores may have more active anti-recipient, donor-
derived effector cells (NK cells and T cell subsets) that may result
in increased cGVHD. Conversely, those with higher inhibitory
KIR scores may have less active populations and be less likely to
develop cGVHD. Given the genotypic potential to inhibit all NK
cells KIR expression may be variable among different clones, and
may affect the development of cGVHD. Further investigation of
KIR expression at the cellular level rather than by genotyping
alone should be pursued.
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CHANGES IN LYMPHOCYTES AND REGULATORY T CELLS IN CHRONIC
GVHD
Tabellini, L.1, Haeusermann, P.1, Flower, M.E.1, Grogan, B.M.1,
Bumgarner, T.E.1, Damodaran, A.C.1, Martin, P.J.1, Hansen, J.A.1
1Fred Hutchinson Cancer Research Center, Seattle, WA.
Regulatory T cells (Treg) are believed to play an important role
in modulating the severity of GVHD and the development of
immunological tolerance after HCT. Studies reported here were
undertaken to determine in more detail the presence and activity of
Treg and interactions with other pathways known to affect regu-
latory function.
Ninety patients were enrolled between 6 and 198 months (me-
dian 19) post-HCT including 6 patients with no prior acute or
chronic GVHD, 64 with prior aGVHD, 72 who developed exten-
sive cGVHD and 18 who had been withdrawn from all immune
suppression therapies (IST). These 90 patients were classiﬁed ac-
cording to current GVHD status and IST: group A, active/un-
treated extensive cGVHD; group B, active cGVHD on high dose
IST; group C, quiescent cGVHD on low IST; group D, tolerant
patients off IST. PBMC were isolated for immunophenotype and
gene expression studies.
Number of CD4 T cells and CD4:CD8 ratio were lower in all
groups compared to controls (p0.02 and 0.03). HLA-DR was
increased in all patients (p0.000) ranging from 14% to 20% of
CD4 and from 34% to 41% of CD8.
The %CD4CD25CD127lo Treg cells in PBL in tolerant was
higher (9.33%) compared to active and quiescent patients (5.9%
and 6.3% respectively, p0.05) and to controls (7.2%, pns).
Gene expression in PBMC was evaluated by real time PCR for
IFNG, IL2RA, IL7R IL10, TGFB and FOXP3. IFNG was in-
creased in active patients compared to controls (p0.02), it tended
to be lower than controls in quiescent and similar to controls in
tolerant patients. IFNG in patients overall correlated with the
%CD8DR (p0.04). IL10 expression was increased in all pa-
tients compared to controls (p0.02) with the highest levels in
quiescent cGVHD. IL10 was lower in tolerant but remained
higher than controls (p0.02). TGFB expression was increased
only in patients with active disease on high dose IST (p0.05).
IL7R was decreased in all patients (p0.000).
FOXP3 expression was signiﬁcantly lower in active and quiescent
cGVHD (p0.02) compared to controls. Average FOXP3 in tol-
erant was similar to controls, however the range for tolerant was
skewed towards below normal levels.
These studies support the theory that FOXP3 plays an important
role in induction of tolerance, but they also suggest a signiﬁcant
role for other immune regulator molecules including TGFB and
IL10. Additional studies will be necessary to more clearly deﬁne
molecular and functional interactions between these regulatory
factors.
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AND CHRONIC GRAFT VERSUS HOST DISEASE, (GVHD), PATIENTS
SUBMITTED TO EXTRACORPOREALPHOTOTHERAPY, (ECP): A STUDY
TO EVALUATE THEIR PREDICTIVE SIGNIFICANCE ON THE GVHD OUT-
COME
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zio Medicina Trasfusionale-Policlinico Sant’Orsola, Bologna, Italy; 2Is-
tituto Di Ematologia Ed Oncologia Seragnoli-Policlinico Sant’Orsola,
Bologna, Italy.
Poster Session II 119
